PT -期刊文章盟虹膜马林Collazo AU -布莱恩Weinshenker AU - Zahra Nasr AU -阿方索洛佩兹TI -长期死亡率Neuromyelitis视谱系障碍(P6.414) DP - 2018年4月10 TA -神经病学PG - P6.414 VI - 90 IP - 15补充4099 - //www.ez-admanager.com/content/90/15_Sup首页plement/P6.414.short 4100 - //www.ez-admanager.com/content/90/15_Supplement/P6.414.full所以Neurology2018 4月10;90 AB -目的:评估患者的长期结果视neuromyelitis谱系障碍(NMOSD)。背景:Pre-aquaporin-4免疫球蛋白研究报告称,五年存活率为68%,平均17.5年(y)的生存。更多的当代研究报告死亡率约25%的那些疾病持续时间不到10年。非裔美国人的种族与更高的死亡率有关。设计/方法:回顾性研究在梅奥诊所的病人评估开始前10月,2006年。结果:143名患者被确认;22(15%)死亡,4男性和18个女性;死亡的平均年龄是58.5 y (41 - 94)。已故的比较与患者生活在这个研究显示:跟进中位数为3 y(范围主和6 y (0-21);疾病持续时间中位数为11个y(3-28)与16 y (9-49);发病的年龄中位数是43(30 - 83)对39个y (21 - 71); median number of relapses was 6 (2–22) versus 5 (5–19); median last known Expanded Disability Status Scale (EDSS) score was 7.5y (4–8) versus 4 (0–8); 21 (95%) received immunotherapy for NMOSD versus 113 (93%); median time to initiation of treatment was 4y (0–21) in those deceased and 5y (0–39) in those living. Among the deceased patients, 16 (73%) were Caucasian, 4 (18%) African American and 2 (9%) of unknown ethnicity, whereas among living patients 72 (60%) Caucasian, 14 (12%) African American, 11 (9%) Hispanic, 8 (3%) Asian, 4 (2%) Native American, 2 (2%) Middle Eastern and 9 (7%) of unknown ethnicity.Conclusions: Patients in this study experienced a lower mortality rate than reported in previous studies. EDSS was identified as a risk factor for mortality.Disclosure: Dr. Marin Collazo has nothing to disclose. Dr. Weinshenker has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Novartis, Alexion, MedImmune, Caladrius Biosciences, Brainstorm Therapeutics. Dr. Nasr has nothing to disclose. Dr. Lopez has nothing to disclose.